ecancer

Meta-analysis of overall survival in multiple myeloma treated with lenalidomide

Dr Philip McCarthy - Roswell Park Cancer Institute, New York, USA

11 Jun 2016

Risk adapted therapy for acute myeloid leukaemia

Prof Jorge Sierra - Hospital de Sant Pau, Barcelona, Spain

11 Jun 2016

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients

Dr Emmanuelle Tchernonog - CHRU Montpellier, Montpellier, France

11 Jun 2016

Blinatumomab improves survival of relapsed B-cell leukaemia

Prof Max Topp - University of Würzburg, Würzburg, Germany

11 Jun 2016

Decoding the risk of thromboembolic events in lymphoma patients

Prof Darko Antic - Clinic For Hematology, Clinical Center Serbia, Belgrade, Serbia

11 Jun 2016

SGN-CD33A combined with HMA therapy produces high remission rates among older patients with AML

Dr Amir Fathi - Massachusetts General Hospital, Boston, USA

11 Jun 2016

Killer antibodies against AML

Dr Mette Hazenberg - AMC, Amsterdam, The Netherlands

11 Jun 2016

Improved survival in adult ALL

Dr Nina Toft - Rigshospitalet, Copenhagen, Denmark

11 Jun 2016

Multiple myeloma highlights from EHA 2016

Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Paul Richardson, Prof Philip McCarthy

10 Jun 2016

Activated JAK-STAT signaling co-operates with HOXA9 to drive leukaemia

Dr Charles De Bock - KU Leuven, Leuven, Belgium

10 Jun 2016

SL401 in patients with rare neoplasm

Prof Naveen Pemmaraju - The University of Texas MD Anderson Cancer Center, Houston, United States

10 Jun 2016

RNA regulation of JAK-STAT pathways in CML

Prof Danilo Perrotti - The University of Maryland Baltimore, Baltimore, USA

10 Jun 2016

More from ecancer